January 25th 2024
The expanded indication makes dupilumab the only approved treatment for eosinophilic esophagitis (EoE) in this age group.
Turning Food Allergy Triggers Into Therapy: A Managed Care Lens on Immunotherapy and Targeted Biologics
1.5 Credits / Immunology
View More
Targeted Therapies for the Management of Eosinophilic Esophagitis Across the Life Cycle: The Role of the Pharmacist in Patient Identification and Optimization, featuring a Pat...
1.5 Credits / Immunology
View More
Managed Care Perspectives on the Burden of Food Allergies and Advances in Treatment
1.5 Credits / Allergy, Immunology
View More
Immunological Characteristics as Potential Treatment Targets in Refractory CRS With Nasal Polyps
October 9th 2019The aim of this study was to assess cytokine levels in patients with refractory chronic rhinosinusitis with nasal polyps and to identify inflammatory markers associated with certain subtypes.
Read More
Adding Dupilumab Improves Outcomes in Patients With Nasal Polyps, Comorbid Asthma
August 26th 2019Results of a subgroup analysis within a randomized, controlled trial show that the monoclonal antibody dupilumab (Dupixent) improved clinical and patient-reported outcomes among patients with chronic rhinosinusitis (CRS) with nasal polyps and comorbid asthma.
Read More
OIT or OIT Plus Biologic? Allergists, Patients Look to Lessen Food Allergy Woes
November 3rd 2018Avoid the allergen. For decades, that was the only advice for people with life threatening food allergies. While that is still true, the food allergy community is cautiously, but excitedly, watching research unfold that could help patients tolerate more of the allergen that might otherwise have serious or deadly consequences.
Read More
Study Quantifies Burden of Atopic Dermatitis on Patients
December 29th 2017Patients with atopic dermatitis (AD) have a significantly greater risk for additional atopic diseases, as well as significantly greater healthcare resource utilization and total cost compared with adults without AD. The burden of AD was generally comparable to that of psoriasis, although patients with AD reported increased use of emergency room visits compared with patients with psoriasis.
Read More
Meta-Analysis Finds Dupilumab Has Most Evidence of Effectiveness for Treating Atopic Dermatitis
December 7th 2017A recent study in The American Journal of Clinical Dermatology led by Igor Snast, MD, sought to evaluate the efficacy and safety of biologic agents in the treatment of atopic dermatitis (AD). The results of the study showed that in particular, dupilumab stood out.
Read More